Abcam, ab249513, Anti-CPOX antibody [EPR11927(B)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal CPOX antibody. Carrier free. Suitable for IP, WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR11927(B),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab249513 is the carrier-free version of
ab169766
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CPOX or coproporphyrinogen oxidase catalyzes the oxidation of coproporphyrinogen III to protoporphyrinogen IX an important step in heme biosynthesis. CPOX possesses a molecular mass of approximately 37–40 kDa. Expression occurs primarily in the mitochondria of liver and bone marrow cells. This enzyme plays a role in maintaining the balance of porphyrin intermediates and prevents accumulation that may cause cellular toxicity.
Biological function summary
CPOX converts coproporphyrinogen III into protoporphyrinogen IX playing a role in the heme biosynthetic pathway. As part of the terminal steps in heme production this transformation is important for synthesizing heme an essential component of hemoglobin myoglobin and various cytochromes. CPOX is not part of any larger enzyme complex but interacts with adjacent enzymes in the metabolic pathway to ensure efficient heme synthesis.
Pathways
CPOX functions in the heme biosynthesis pathway. This pathway is vital for the production of heme enabling the synthesis of hemoglobin and electron transport chains. CPOX acts sequentially after coproporphyrinogen III oxidase and before protoporphyrinogen IX oxidase. The enzyme works in concert with proteins such as uroporphyrinogen III synthase (UROS) in earlier steps of the pathway affecting overall heme production efficiency.
Mutations or defects in CPOX can lead to hereditary coproporphyria (HCP) a disorder characterized by neurovisceral attacks and photosensitivity. This condition results from the accumulation of porphyrins due to a dysfunctional heme synthesis pathway. Additionally CPOX-related dysfunction can have implications in liver disorders affecting the balance of heme precursors. Improved understanding of CPOX and its interactions with proteins like UROS can provide insight into therapeutic targets for these conditions.